Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the EU / 2024-518609-17-00
Authorised, recruiting Phase II

The effect of CBD on sleep quality following late evening exercise

2024-518609-17-00 · tracked via the Priya Life Science EU tracker
Sponsor
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Physiological processes
Decision date
21/01/2026
Enrollment target
20
Sites
Belgium

Condition studied

healthy individuals

Investigational medicinal product(s)

CannabidiolSoftisan 378

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

Changes in sleep efficiency between different sessions

Endpoint detail

Changes in other sleep indices between different sessions, Changes in perceived sleep quality between different sessions, Changes in circulating hormones involved in sleep and stress between different sessions, Changes in plasma catecholamines and serotonin between different sessions, Changes urinary catecholamine and serotonin excretion between different sessions

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-518609-17-00 on CTIS ↗ ← All trials in the EU